Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immunohistochemistry

Nakaguchi, Hiroshi; Fujimaki, Takamitsu; Matsuno, Akira; Matsuura, Reiko; Asai, Akio; Suzuki, Ichirô; Sasaki, Tomio; Kirino, Takaaki

doi:10.1002/(sici)1097-0142(19990515)85:10<2249::aid-cncr21>3.0.co;2-5

Cited by 70 publications

(33 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24) Therefore, the clinical course of benign meningioma is not necessarily favorable, 30) and many studies have investigated the prediction of postoperative recurrence, 16,18,22) particularly after total resection, usually based on the clinical or imaging findings of patients, but recently mainly based on the tumor growth potential, that is MIB-1 index. 14,15,17,18,31,32,34) MIB-1 index can be used as an index within a facility, but general comparison is difficult because no standard measurement method has been established, and the value markedly varies depending on the measurement site within a preparation. 18,19) Subsequently, the MIB-1 index considered to predict a high risk of recurrence or regrowth varies from 2% to 5%, 15,17,18,31) but the WHO classification considers that the mean MIB-1 index of grade I benign meningioma is generally 3.8%, showing the problem as a general predictor of regrowth in global criteria.…”

Section: Discussionmentioning

confidence: 99%

“…The therapeutic strategy for residual tumors or the course after total resection has recently been based on the MIB-1 index, as an indicator of the proliferative potential of tumors. 14,15,17,18,31,32,34) However, the MIB-1 index has various problems, 18,19) so may be used as a criterion within a facility, but is difficult to use as a global standard for evaluation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Radiological Predictive Factors for Regrowth of Residual Benign Meningiomas

Fujimoto¹,

Ishida²,

Uchiyama³

et al. 2011

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

The pre-and postoperative radiological predictive factors for the regrowth of residual benign meningiomas were investigated in 80 of 327 patients who underwent first surgery for intracranial meningioma, who met the following conditions: residual tumor observed on postoperative imaging, follow up for more than 5 years or until regrowth of the residual tumor, histological diagnosis of World Health Organization grade I, and no additional therapy performed within 1 month after surgery. These 80 patients were divided into those with no regrowth during the follow-up period (Group A, n ＝ 54) and those with regrowth (Group B, n ＝ 26), and the clinical characteristics and pre-and postoperative imaging findings were compared. Univariate analysis of factors influencing regrowth showed 6 factors were significant: tumor size AE4 cm (p ＝ 0.043), tumor volume AE30 cm 3 (p ＝ 0.026), presence of edema (p ＝ 0.036), unclear brain-tumor interface (p º 0.001), presence of a pial-cortical blood supply (p ＝ 0.031), and residual tumor volume AE3.0 cm 3 (p º 0.001). Multivariate analysis showed only residual tumor volume AE3.0 cm 3 was significant (p ＝ 0.001). Generally, the significant imaging findings on univariate analysis suggest malignant meningioma. Similar findings may be observed even in grade I cases, and residual tumors may regrow in such cases. The possibility is particularly high if the residual tumor volume exceeds 3.0 cm 3 , so early radiotherapy should be performed to prevent regrowth.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Radiological Predictive Factors for Regrowth of Residual Benign Meningiomas

Fujimoto¹,

Ishida²,

Uchiyama³

et al. 2011

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

show abstract

“…[3][4][5][6][7][8][9][10][11][12] Single studies are unable to show the importance of MIB-1 immunoreactivity for prediction of meningioma outcome. 13,14 We hypothesize that further study into the clinical utility of proteins involved in the regulation of cell cycle control and apoptosis is a fruitful avenue of investigation to identify more reliable prognostic indicators of meningioma recurrence.…”

mentioning

confidence: 99%

Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome

Korshunov

Шишкина

Golanov

2003

Intl Journal of Cancer

View full text Add to dashboard Cite

Routine pathological examination cannot distinctively predict the clinical course of meningiomas because even histologically benign tumors may recur after gross total resection. Numerous efforts have been made for the evaluation of different immunohistochemical assays in meningioma prognosis. We investigated the prognostic significance of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression by immunohistochemical analysis of 271 meningiomas. All tumors were additionally stained for the proliferation markers Ki-67 and DNA topoisomerase II alpha (TopoII␣). Significant differences between the number of p16INK4a-, p18INK4c-and p21CIP1-positive cases were noted among the 3 grades of meningiomas. p16INK4a-and p21CIP-positive tumors were found to prevail among benign meningiomas, whereas p18INK4c immunostaining was closely associated to anaplastic meningiomas. The number of p16INK4a-and p21CIP-positive cases was significantly lower in the cohort of recurrent meningiomas. In contrast, p18INK4c-positive cases were clustered among recurrent meningiomas regardless of tumor grade. Immunoreactivity of p14ARF, p27KIP1 and p73 did not show any differences between meningiomas of various histology and clinical outcomes. Multivariate analysis revealed that only tumor grade and TopoII␣ index are independent criteria for predicting meningioma recurrence. Thus, the immunohistochemical assessment of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in meningiomas does not appear to provide prognostically useful information. Further studies are needed to identify more reliable prognostic markers and to address in more detail the role of cell cycle aberrations in these tumors.

show abstract

“…The Mib-1 monoclonal antibody, staining for the Ki-67 antigen, has been used to estimate meningioma growth and recurrence potential [2,19,22,23,26]. Furthermore the expression of progesterone receptors in meningiomas seems to indicate a more benign clinical behavior of these tumors [4,6].…”

Section: Discussionmentioning

confidence: 99%